Overview
Prospective observational multicenter study, aimed at evaluating the effectiveness on local control and cancer-specific survival of radiochemotherapy followed by interventional radiotherapy in patients affected by vaginal cancer
Description
Prospective observational multicenter study, aimed at evaluating the effectiveness on local control and cancer-specific survival of radiochemotherapy (45Gy on pelvis and tumor plus chemotherapy with cisplatinum) followed by interventional radiotherapy (28Gy on residual tumor) in patients affected by vaginal cancer
Eligibility
Inclusion Criteria:
- Age more than18 years old
- Performance status 0,1
- Hystological diagnosis of squamous vaginal cancer
- HPV, p16, p53 status
- Stage I, II, III and IV (AJCC 2018th version)
- Stadiation with magnetic resonance and positron emission tomography
- Informed consensus
Exclusion Criteria:
- Age inferior 18 years old
- Performance status more than 2
- Previous cancer in the last ten years
- Previous radiation treatment in the region of interest
- Presence of pathologies that contraindicate radiotherapy treatment (genetic syndromes of hyper-radiosensitivity, ulcerative colitis, diverticulitis in the acute phase, severe diverticulosis, chronic pelvic inflammation)
- Presence of internal pathologies that contraindicate chemotherapy or radio-chemotherapy treatment (severe liver disease, heart disease, renal failure, etc.)
- Presence of distant metastases in sites other than the pelvic lymph nodes
- Any significant medical condition that in the opinion of the investigator may interfere with the patient's optimal participation in the study